Combined Inhibition of KRAS G12C and PD1 Boosts Therapeutic Efficacy via Conditioning of Tumor Microenvironment

The G12C mutation is one of the most frequent KRAS mutations in non–small cell lung cancer (NSCLC), and oncogenic RAS signaling has been shown to promote an immunosuppressive tumor microenvironment by upregulating PD-L1 expression.  At SITC 2023, WuXi AppTec scientists presented a poster showing that combination therapy of the KRAS G12C inhibitor AMG 510 with the anti-PD-1 antibody nivolumab resulted in significant anti-tumor activities in preclinical humanized NSCLC mouse models.

SITC 2023_Combined inhibition of KRAS G12C and PD1 boosts therapeutic efficacy via conditioning of tumor microenvironment


← Return to Resources
× peptide, amino acid

Contact An Expert Today!